Developing therapeutic approaches for metachromatic leukodystrophy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal disorder caused by the deficiency of arylsulfatase A (ASA), resulting in impaired degradation of sulfatide, an essential sphingolipid of myelin. The clinical manifestations of MLD are characterized by progressive demyelination and subsequent neurological symptoms resulting in severe debilitation. The availability of therapeutic options for treating MLD is limited but expanding with a number of early stage clinical trials already in progress. In the development of therapeutic approaches for MLD, scientists have been facing a number of challenges including blood-brain barrier (BBB) penetration, safety issues concerning therapies targeting the central nervous system, uncertainty regarding the ideal timing for intervention in the disease course, and the lack of more in-depth understanding of the molecular pathogenesis of MLD. Here, we discuss the current status of the different approaches to developing therapies for MLD. Hematopoietic stem cell transplantation has been used to treat MLD patients, utilizing both umbilical cord blood and bone marrow sources. Intrathecal enzyme replacement therapy and gene therapies, administered locally into the brain or by generating genetically modified hematopoietic stem cells, are emerging as novel strategies. In pre-clinical studies, different cell delivery systems including microencapsulated cells or selectively neural cells have shown encouraging results. Small molecules that are more likely to cross the BBB can be used as enzyme enhancers of diverse ASA mutants, either as pharmacological chaperones, or proteostasis regulators. Specific small molecules may also be used to reduce the biosynthesis of sulfatides, or target different affected downstream pathways secondary to the primary ASA deficiency. Given the progressive neurodegenerative aspects of MLD, also seen in other lysosomal diseases, current and future therapeutic strategies will be complementary, whether used in combination or separately at specific stages of the disease course, to produce better outcomes for patients afflicted with this devastating inherited disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 1×
“132 PRs work by interacting with the ER folding components and eventually activating physiological cellular response mechanisms, including unfolded protein response and heat shock proteins (Figure 2).”
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Priller, J., Flügel, A., Wehner, T., Boentert, M., Haas, C. A., Prinz, M., Fernández-Klett, F., Prass, K., Bechmann, I., de Boer, B. A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1356 · Cited by 637
FOXO3A directs a protective autophagy program in haematopoietic stem cells
Warr, M. R., Binnewies, M., Flach, J., Reynaud, D., Garg, T., Malhotra, R., Debnath, J., & Passegué, E. (2013) · Nature · doi:10.1038/nature11895 · Cited by 625 · cited 2×
“68 Thus, the impaired autophagy pathway in lysosomal disorders can lead to apoptosis.”
Central nervous system myelin: structure, synthesis and assembly
Aggarwal, S., Yurlova, L., & Simons, M. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.06.004 · Cited by 301 · cited 9×
“Sulfatides are abundant in both the CNS and PNS.”
InfluentialImgrund, S., Hartmann, D., Farwanah, H., Eckhardt, M., Sandhoff, R., Degen, J., Gieselmann, V., Sandhoff, K., & Willecke, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031971 · Cited by 299 · cited 3×
“The CerS2 knockout mice showed decreased levels of galactosylceramide, sulfatide, and very long-chain fatty acids.(56) From early adulthood, the CerS2 null mice showed progressive myelin instability, with 50% loss of the compacted myelin pattern and ∼80% loss of myelin-basic protein.”
InfluentialAn Adaptable Standard for Protein Export from the Endoplasmic Reticulum
Wiseman, R. L., Powers, E. T., Buxbaum, J. N., Kelly, J. W., & Balch, W. E. (2007) · Cell · doi:10.1016/j.cell.2007.10.025 · Cited by 155 · cited 3×
“127 Interestingly, these two classes of small molecules can work together synergistically to guide the mis-folded mutant enzyme to a folded state (assisted by PRs) and maintain its structural stability (assisted by PCs).”
Cited by
Gene therapy for metachromatic leukodystrophy
Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R. G., & Sondhi, D. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23792 · Cited by 91
Rosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58
“There are currently no approved therapies for metachromatic leukodystrophy (Batzios and Zafeiriou, 2012; Patil and Maegawa, 2013).”
BackgroundInfluentialRosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41
Metadata
- Authors
- Maegawa, G., & Patil
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-08
- Volume
- 7
- Pages
- 729
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2091739816
- Cited by
- 77
- References
- 8
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developing therapeutic approaches for metachromatic leukodystrophy. https://app.cochat.ai/papers/10.2147/dddt.s15467
- The paper
- Maegawa, G., & Patil. (2013). Developing therapeutic approaches for metachromatic leukodystrophy. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s15467
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.